CPIC® Guideline for Tacrolimus and CYP3A5

Most recent guideline publication:

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015)

Updates since publication:

No updates on dosing recommendations since publication.

Tables provided in the main manuscript of the guideline:

Table 1. Assignment of likely metabolism phenotypes based on CYP3A5 diplotypes
Table 2. Dosing recommendations for tacrolimus based on CYP3A5 phenotype

Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015)

Tables and figures included in the supplementa or referenced in the guideline:

Supplemental Table S1. Genotypes that constitute the * alleles for CYP3A5 For an updated version of this table see the CYP3A5 allele definition table .
Supplemental Table S2. Association between allelic variants and CYP3A5 function For an updated version of this table see the CYP3A5 allele functionality table .
Supplemental Table S3. Frequencies of CYP3A5 alleles in major race/ethnic groups For an updated version of this table see the CYP3A5 frequency table .
Supplemental Table S4. Evidence linking CYP3A5*1, *3, *6 and *7 (rs776746, rs10264272 and rs41303343) genotype with phenotype
Supplemental Table S5. Drug(s) that pertain to this guideline
Supplemental Table S6. Gene(s) that pertain to this guideline For an updated version of this table see the CYP3A5 gene resource mappingsb.
Supplemental Figure S1. CYP3A5 pharmacogenetic test result: clinical implementation workflow for EHR
Supplemental Figure S2. CYP3A5 genotype and tacrolimus: point of care clinical decision support
Supplemental Table S7. Example implementation of this guideline for CYP3A5: pharmacogenetic diplotype/phenotype summary entries For an updated version of this table see the Implementation workflow and CYP3A5 consult b
Supplemental Table S8. Example Implementation of this guideline: point of care clinical decision support

aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.

bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.

This guideline has been endorsed by the American Society of Health-System Pharmacists (ASHP).